|
|
Volumn 13, Issue 7, 2002, Pages 993-994
|
|
Trastuzumab therapy for the metastatic patient: Does the primary match?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
BREAST CANCER;
CANCER LOCALIZATION;
CONTROLLED STUDY;
DIAGNOSTIC KIT;
DRUG INDICATION;
EDITORIAL;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENE AMPLIFICATION;
GENE OVEREXPRESSION;
HISTOPATHOLOGY;
HUMAN;
HUMAN TISSUE;
IMMUNOHISTOCHEMISTRY;
METASTASIS;
ONCOGENE NEU;
PRIORITY JOURNAL;
PROTEIN DEGRADATION;
TUMOR BIOPSY;
TUMOR LOCALIZATION;
BREAST TUMOR;
CONTROLLED CLINICAL TRIAL;
FEMALE;
MORTALITY;
NEEDLE BIOPSY;
NOTE;
PATHOLOGY;
PROGNOSIS;
RISK ASSESSMENT;
SURVIVAL;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BIOPSY, NEEDLE;
BREAST NEOPLASMS;
CONTROLLED CLINICAL TRIALS;
FEMALE;
HUMAN;
NEOPLASM METASTASIS;
PROGNOSIS;
RECEPTOR, ERBB-2;
RISK ASSESSMENT;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
HUMANS;
|
|
EID: 0035990821
PISSN: 09237534
EISSN: None
Source Type: Journal
DOI: 10.1093/annonc/mdf295 Document Type: Editorial |
|
Times cited : (10)
|
|
References (9)
|
